In human NP cells, the use of JNK pathway inhibitors can counteract interleukin 17 (IL-17)-induced COX2/PGE2 production and IVD inflammation, which may be a potential therapeutic target for alleviating IDD (51). Here, IL17A is linked to intervertebral disk degenerative disorder.